drugset / Trial / NCT01585935

Preventing Cholestasis Using SMOFLipid®

NCT01585935

Phase 4 Completed 230 enrolled Medical University of Vienna
RandomizedParallel-groupTriple-blindPrevention

Summary

Preterm infants of extreme low birth weight (ELBW, \< 1000 gram birth weight) cannot immediately be nourished with mother´s or formula milk and are typically dependent on parenteral nutrition (PN) for a prolonged period of time. This puts them at risk for liver complications of PN, namely parenteral nutrition associated cholestasis (PNAC). Intravenous lipid emulsions (ILE) based on soy bean oil are standard of care for provision of energy and essential fatty acids in preterm infants. However, they might be implicated in the pathogenesis of PNAC. ILEs based on pure fish oil are proposed for therapy of PNAC. Recently a lipid emulsion containing 15 % fish oil together with soy bean, olive and MCT oil has become available in Europe (SMOFLIPID®). Such a balanced lipid emulsion might be more favourable than the standard soy bean oil emulsion (Intralipid®) concerning the development of PNAC. Furthermore ILEs containing fish oil might exert a positive effect on neurodevelopment. However, there are no data so far. The study aims to evaluate the fish oil containing ILE "SMOFlipid®" for its protective effect against PNAC in ELBW infants compared to standard treatment with the soy bean based ILE "Intralipid®". Furthermore neurodevelopment at 12 and 24 months of corrected gestational age will be investigated.

Timeline

Start
2012-06
Primary completion
2015-06
Completion
2017-11-13

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Intralipid Other / unclassified 3 g/kg Intravenous
Subject SMOFlipid Other / unclassified 3 g/kg Intravenous